lobbying_activities: 2142781

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2142781	e91b492c-3c69-40e2-8f70-82ef2d73a690	Q2	APOTEX CORP.	310973	APOTEX CORP.	2018	second_quarter	PHA	S. 974/H.R. 2212, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; S. 2476, the Expanding Access to Low Cost Generics Act, provisions relating to pharmaceutical market blockages caused by "parked" Hatch-Waxman 180 day exclusivity periods; Federal policy relating to the Trump Administration's Fiscal Year 2019 Budget proposal to address pharmaceutical market blockages caused by parked Hatch-Waxman 180 day exclusivity periods; S. 124, the Preserve Access to Affordable Generics Act, provisions relating to pharmaceutical patent settlements between generic and brand drug manufacturers; and Federal policy relating to the impact of rebates on the development of the biosimilars market.	HOUSE OF REPRESENTATIVES,SENATE		160000	0	0	2018-07-12T09:42:19.997000-04:00